Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2022-02-18 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于股东Jumbo Kindness Limited（巨慈有限公司）减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the results of a shareholder's reduction in shareholding. It details the shareholder's initial holdings, the planned reduction, the actual shares reduced, and the current holdings after the reduction. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, specifically reporting a change in significant share ownership levels. The document length is short and focused solely on shareholding changes, confirming it is not a full financial report or other type of filing.
2022-02-18 Chinese
成都先导药物开发股份有限公司关于股东重庆渤溢新天股权投资基金合伙企业（有限合伙）减持时间过半暨减持股份进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a shareholder's share reduction plan, including details on the number of shares held before and after the reduction, the reduction period, methods, prices, and the impact on company control. It is a notification about a shareholder's transaction in their own shares rather than a financial report or earnings release. The document length is short (1828 characters) and it focuses on shareholding changes by a specific shareholder. This fits the definition of 'Transaction in Own Shares' (POS) rather than other categories like Major Shareholding Notification (MRQ) or Capital/Financing Update (CAP).
2022-01-26 Chinese
成都先导药物开发股份有限公司关于自愿披露HG030片临床试验申请获得FDA批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chengdu Lead Drug Development Co., Ltd. regarding the FDA approval for clinical trial application of their drug HG030. It includes details about the drug, its development, and risk warnings. The document is relatively short (1610 characters) and serves as a disclosure of a regulatory event rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval and related information that does not fit other specific categories.
2022-01-24 Chinese
成都先导药物开发股份有限公司关于持股5%以上股东减持达到1%的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement regarding the reduction of shareholding by shareholders holding more than 5% of the company's shares. It details the shareholding changes, percentages, and confirms that the changes do not affect control or governance. The document is titled as a "提示性公告" (prompting announcement) about shareholding changes and does not contain financial statements or detailed financial analysis. It is a notification of a major shareholding change, specifically a reduction in shareholding by significant shareholders. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 2506 characters, which is consistent with a typical announcement rather than a full report.
2022-01-18 Chinese
成都先导药物开发股份有限公司关于持股5%以上股东拉萨经济技术开发区华博医疗器械有限公司减持达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a shareholder holding more than 5% of shares reducing their stake by more than 1%. It details the shareholder's name, the number of shares held before and after the reduction, the dates of the transactions, and confirms that the reduction does not affect control or governance. There is no financial statement or report content, only a disclosure of shareholding changes. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2022-01-17 Chinese
成都先导药物开发股份有限公司关于股东Jumbo Kindness Limited（巨慈有限公司）减持数量过半暨减持股份进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the reduction of shareholding by a specific shareholder, Jumbo Kindness Limited, including details about the number of shares reduced, the percentage of total shares, the method of reduction, and the impact on the company. It does not contain financial statements or detailed financial performance data. It is a notification about a shareholder's transaction in the company's shares. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares or shareholders reducing their holdings. The document length is 2207 characters, which is relatively short and focused on shareholding changes, not a full financial report or regulatory filing. Therefore, the correct classification is POS with high confidence.
2022-01-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.